{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T18:03:42Z","timestamp":1773943422250,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["NIHR203182"],"award-info":[{"award-number":["NIHR203182"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pilot Feasibility Stud"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Incidence of gestational diabetes mellitus (GDM) is increasing and is associated with adverse perinatal outcomes including macrosomia, pre-eclampsia, and pre-term delivery. Optimum glycaemic control can reduce these adverse perinatal outcomes. Continuous glucose monitoring (CGM) informs users about interstitial glucose levels allowing early detection of glycaemic excursions and pharmacological or behavioural intervention. Few adequately powered RCTs to evaluate the impact of using CGM in women with GDM on perinatal outcomes have been undertaken.<\/jats:p>\n                    <jats:p>We aim to establish the feasibility of a multi-site RCT to evaluate the clinical- and cost-effectiveness of an intermittently scanned continuous glucose monitor (isCGM) compared with self-monitored blood glucose (SMBG) in women with GDM for reducing fetal macrosomia and improving maternal and fetal outcomes. We will evaluate recruitment and retention rates, adherence to device requirements, adequacy of data capture and acceptability of trial design and isCGM devices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Open-label multicentre randomised controlled feasibility trial. Inclusion criteria: pregnant women, singleton pregnancy, recent diagnosis of GDM (within 14\u00a0days of commencing medication, up to 34\u00a0weeks gestation) prescribed metformin and\/or insulin. Women will be consecutively recruited and randomised to isCGM (FreestyleLibre2) or SMBG. At every antenatal visit, glucose measurements will be evaluated. The SMBG group will use blinded isCGM for 14\u00a0days at baseline (~\u200912\u201332\u00a0weeks) and\u2009~\u200934\u201336\u00a0weeks. The primary outcome is the recruitment rate and absolute number of women participating. Clinical assessments of maternal and fetal\/infant health will be undertaken at baseline, birth, up to\u2009~\u200913\u00a0weeks post-natal. Psychological, behavioural and health economic measures will be assessed at baseline and\u2009~\u200934\u201336\u00a0weeks gestation. Qualitative interviews will be undertaken with study decliners, participants, and professionals to explore trial acceptability, of using isCGM and SMBG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>GDM can be associated with adverse pregnancy outcomes. isCGM could offer a timely, easy-to-engage-with intervention, to improve glycaemic control, potentially reducing adverse pregnancy, birth and long-term health outcomes for mother and child. This study will determine the feasibility of conducting a large-scale multisite RCT of isCGM in women with GDM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      This study has been registered with the ISRCTN (reference:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN42125256\">ISRCTN42125256<\/jats:ext-link>\n                      , Date registered: 07\/11\/2022).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40814-023-01341-y","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T05:02:31Z","timestamp":1689051751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Protocol for a multi-site randomised controlled feasibility study investigating intermittently scanned blood continuous\u00a0glucose monitoring use\u00a0for gestational diabetes: the RECOGNISE study"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0743-6547","authenticated-orcid":false,"given":"Anna","family":"Davies","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0371-731X","authenticated-orcid":false,"given":"Erik","family":"Lenguerrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5395-8261","authenticated-orcid":false,"given":"Eleanor","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-9536","authenticated-orcid":false,"given":"Rebecca","family":"Kandiyali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Douek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-6953","authenticated-orcid":false,"given":"Jane","family":"Norman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9178-102X","authenticated-orcid":false,"given":"Abi","family":"Loose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-4080","authenticated-orcid":false,"given":"Lynn","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Timlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6409-5238","authenticated-orcid":false,"given":"Christy","family":"Burden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"1341_CR1","first-page":"2017","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2017","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. Brussels: International Diabetes Federation; 2017. p. 2017."},{"key":"1341_CR2","unstructured":"National Institute for Health and Care Excellence (NICE) Diabetes in Pregnancy London. 2015. Available from: https:\/\/www.nice.org.uk\/guidance\/ng3\/chapter\/Recommendations#gestational-diabetes-2."},{"key":"1341_CR3","unstructured":"NICE. Diabetes in pregnancy: management from preconception to the postnatal period: NICE; 2015. Available from: https:\/\/www.nice.org.uk\/guidance\/ng3\/chapter\/Recommendations#antenatal-care-for-women-with-diabetes."},{"issue":"3","key":"1341_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10995-014-1553-5","volume":"19","author":"A Correa","year":"2015","unstructured":"Correa A, Bardenheier B, Elixhauser A, Geiss LS, Gregg E. Trends in prevalence of diabetes among delivery hospitalizations, United States, 1993\u20132009. Matern Child Health J. 2015;19(3):635\u201342.","journal-title":"Matern Child Health J"},{"key":"1341_CR5","volume-title":"Hospitalizations related to diabetes in pregnancy, 2008: Statistical Brief #102. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs","author":"LM Wier","year":"2006","unstructured":"Wier LM, Witt E, Burgess J, Elixhauser A. Hospitalizations related to diabetes in pregnancy, 2008: Statistical Brief #102. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006."},{"issue":"9","key":"1341_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2337\/dc17-0369","volume":"40","author":"E Cosson","year":"2017","unstructured":"Cosson E, Baz B, Gary F, Pharisien I, Nguyen MT, Sandre-Banon D, et al. Poor reliability and poor adherence to self-monitoring of blood glucose are common in women with gestational diabetes mellitus and may be associated with poor pregnancy outcomes. Diabetes Care. 2017;40(9):1181\u20136.","journal-title":"Diabetes Care"},{"issue":"1","key":"1341_CR7","doi-asserted-by":"publisher","first-page":"S575","DOI":"10.1016\/j.ajog.2017.11.460","volume":"218","author":"E Ashwal","year":"2018","unstructured":"Ashwal E, Miron E, Hadar E, Wiznitzer A, Toledano Y. 973: The impact of glucose variability on fetal growth in Type 1 diabetes patients. Am J Obstet Gynecol. 2018;218(1):S575.","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 2","key":"1341_CR8","first-page":"14","volume":"66","author":"KC Kamana","year":"2015","unstructured":"Kamana KC, Shakya S, Zhang H. Gestational diabetes mellitus and macrosomia: a literature review. Ann Nutr Metab. 2015;66(Suppl 2):14\u201320.","journal-title":"Ann Nutr Metab."},{"issue":"19","key":"1341_CR9","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa0707943","volume":"358","author":"BE Metzger","year":"2008","unstructured":"Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991\u20132002.","journal-title":"N Engl J Med"},{"issue":"8","key":"1341_CR10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/1471-0528.15659","volume":"126","author":"T Stacey","year":"2019","unstructured":"Stacey T, Tennant P, McCowan L, Mitchell EA, Budd J, Li M, et al. Gestational diabetes and the risk of late stillbirth: a case-control study from England. BJOG. 2019;126(8):973\u201382.","journal-title":"UK Bjog"},{"issue":"14","key":"1341_CR11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1056\/NEJMoa0902430","volume":"361","author":"MB Landon","year":"2009","unstructured":"Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"1341_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2337\/dc18-2212","volume":"42","author":"GR Law","year":"2019","unstructured":"Law GR, Alnaji A, Alrefaii L, Endersby D, Cartland SJ, Gilbey SG, et al. Suboptimal nocturnal glucose control is associated with large for gestational age in treated gestational diabetes mellitus. Diabetes Care. 2019;42(5):810\u20135.","journal-title":"Diabetes Care"},{"issue":"4","key":"1341_CR13","first-page":"633","volume":"101","author":"Y Yogev","year":"2003","unstructured":"Yogev Y, Chen R, Ben-Haroush A, Phillip M, Jovanovic L, Hod M. Continuous glucose monitoring for the evaluation of gravid women with type 1 diabetes mellitus. Obstet Gynecol. 2003;101(4):633\u20138.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"1341_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13300-019-00720-0","volume":"11","author":"M Evans","year":"2020","unstructured":"Evans M, Welsh Z, Ells S, Seibold A. The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies. Diabetes Ther. 2020;11(1):83\u201395.","journal-title":"Diabetes Ther"},{"issue":"S3","key":"1341_CR15","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1089\/dia.2017.0035","volume":"19","author":"D Rodbard","year":"2017","unstructured":"Rodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther. 2017;19(S3):S25-s37.","journal-title":"Diabetes Technol Ther"},{"issue":"10110","key":"1341_CR16","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/S0140-6736(17)32400-5","volume":"390","author":"DS Feig","year":"2017","unstructured":"Feig DS, Donovan LE, Corcoy R, Murphy KE, Amiel SA, Hunt KF, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390(10110):2347\u201359.","journal-title":"Lancet"},{"key":"1341_CR17","unstructured":"NICE. Diabetes in pregnancy: management from preconception to the postnatal period: NICE; 2015. Available from: https:\/\/www.nice.org.uk\/guidance\/ng3\/resources\/diabetes-in-pregnancy-management-from-preconception-to-the-postnatal-period-pdf-51038446021."},{"issue":"10","key":"1341_CR18","first-page":"Cd01069","volume":"10","author":"P Raman","year":"2017","unstructured":"Raman P, Shepherd E, Dowswell T, Middleton P, Crowther CA. Different methods and settings for glucose monitoring for gestational diabetes during pregnancy. Cochrane Database Syst Rev. 2017;10(10):Cd01069.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"1341_CR19","doi-asserted-by":"publisher","first-page":"e14703","DOI":"10.1111\/dme.14703","volume":"39","author":"RM Garc\u00eda-Moreno","year":"2022","unstructured":"Garc\u00eda-Moreno RM, Ben\u00edtez-Valderrama P, Barquiel B, Gonz\u00e1lez P\u00e9rez-de-Villar N, Hillman N, Lora Pablos D, et al. Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Diabet Med. 2022;39(1):e14703.","journal-title":"Diabet Med"},{"key":"1341_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13098-016-0161-5","volume":"8","author":"E Alfadhli","year":"2016","unstructured":"Alfadhli E, Osman E, Basri T. Use of a real time continuous glucose monitoring system as an educational tool for patients with gestational diabetes. Diabetol Metab Syndr. 2016;8:48.","journal-title":"Diabetol Metab Syndr"},{"key":"1341_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fendo.2019.00697","volume":"10","author":"Q Yu","year":"2019","unstructured":"Yu Q, Aris IM, Tan KH, Li LJ. Application and utility of continuous glucose monitoring in pregnancy: a systematic review. Front Endocrinol. 2019;10:697.","journal-title":"Front Endocrinol&nbsp;"},{"key":"1341_CR22","unstructured":"MMBRACE. Lessons learned to inform maternity care from the UK and Ireland confidential Enquiries into Maternal Deaths and Morbidity 2016\u201318 2020. Available from: https:\/\/www.npeu.ox.ac.uk\/assets\/downloads\/mbrrace-uk\/reports\/maternal-report-2020\/MBRRACE-UK_Maternal_Report_Dec_2020_v10.pdf."},{"key":"1341_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200\u20137.","journal-title":"Ann Intern Med."},{"key":"1341_CR24","unstructured":"NICE. Improving inclusion of under-served groups in clinical research: Guidance from INCLUDE project 2020. Available from: https:\/\/www.nihr.ac.uk\/documents\/improving-inclusion-of-under-served-groups-in-clinical-research-guidance-from-include-project\/25435."},{"issue":"13","key":"1341_CR25","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2016;26(13):1753\u201360.","journal-title":"Qual Health Res"},{"key":"1341_CR26","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2010."},{"key":"1341_CR27","unstructured":"Abbott. FreeStyle academy 2022. Available from: https:\/\/progress.freestylediabetes.co.uk\/."},{"key":"1341_CR28","unstructured":"Sensyne. GDm-Health 2022. Available from: https:\/\/www.sensynehealth.com\/training\/gdm-health-help-centre."},{"key":"1341_CR29","volume-title":"Health app: GDm-Health for people with gestational diabetes","author":"NICE","year":"2017","unstructured":"NICE. Health app: GDm-Health for people with gestational diabetes. 2017."},{"issue":"6","key":"1341_CR30","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1007\/s00125-020-05123-6","volume":"63","author":"AM Egan","year":"2020","unstructured":"Egan AM, Bogdanet D, Griffin TP, Kgosidialwa O, Cervar-Zivkovic M, Dempsey E, et al. A core outcome set for studies of gestational diabetes mellitus prevention and treatment. Diabetologia. 2020;63(6):1120\u20137.","journal-title":"Diabetologia"},{"issue":"15","key":"1341_CR31","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1001\/jama.1958.03000150027007","volume":"168","author":"V Apgar","year":"1958","unstructured":"Apgar V, Holaday DA, James LS, Weisbrot IM, Berrien C. Evaluation of the newborn infant; second report. J Am Med Assoc. 1958;168(15):1985\u20138.","journal-title":"J Am Med Assoc"},{"key":"1341_CR32","unstructured":"NICE. Hypertension in pregnancy: diagnosis and management. NICE guideline (NG133) 2019. Available from: https:\/\/www.nice.org.uk\/guidance\/ng133."},{"issue":"12","key":"1341_CR33","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1089\/dia.2019.0189","volume":"21","author":"Speight","year":"2019","unstructured":"Speight. Development and psychometric validation of the novel glucose monitoring experiences questionnaire among adults with type 1 diabetes. Diabetes Technol Ther. 2019;21(12):691\u2013701.","journal-title":"Diabetes Technol Ther."},{"issue":"10","key":"1341_CR34","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1249\/01.MSS.0000142303.49306.0D","volume":"36","author":"L Chasan-Taber","year":"2004","unstructured":"Chasan-Taber L, Schmidt MD, Roberts DE, Hosmer D, Markenson G, Freedson PS. Development and validation of a Pregnancy Physical Activity Questionnaire. Med Sci Sports Exerc. 2004;36(10):1750\u201360.","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"1341_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1017\/S1368980016002275","volume":"20","author":"CY England","year":"2017","unstructured":"England CY, Thompson JL, Jago R, Cooper AR, Andrews RC. Development of a brief, reliable and valid diet assessment tool for impaired glucose tolerance and diabetes: the UK Diabetes and Diet Questionnaire. Public Health Nutr. 2017;20(2):191\u20139.","journal-title":"Public Health Nutr"},{"issue":"10","key":"1341_CR36","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s10620-019-05621-7","volume":"64","author":"CI Voils","year":"2019","unstructured":"Voils CI, King HA, Thorpe CT, Blalock DV, Kronish IM, Reeve BB, et al. Content validity and reliability of a self-report measure of medication nonadherence in hepatitis C treatment. Dig Dis Sci. 2019;64(10):2784\u201397.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"1341_CR37","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"1341_CR38","first-page":"1","volume-title":"sf-36v2 health survey: administration guide for clinical trial Investigators","author":"JE Ware","year":"2008","unstructured":"Ware JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. sf-36v2 health survey: administration guide for clinical trial Investigators. Lincoln, RI: QualityMetric Incorporated; 2008. p. 1\u201334."},{"issue":"2","key":"1341_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","volume":"21","author":"J Brazier","year":"2002","unstructured":"Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271\u201392.","journal-title":"J Health Econ"},{"key":"1341_CR40","unstructured":"Euroqol. The EQ-5D-5L 2009. Available from: https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/."},{"issue":"8","key":"1341_CR41","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593\u2013603.","journal-title":"Diabetes Care"},{"issue":"3","key":"1341_CR42","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10198-018-1006-y","volume":"20","author":"N Fitria","year":"2019","unstructured":"Fitria N, van Asselt ADI, Postma MJ. Cost-effectiveness of controlling gestational diabetes mellitus: a systematic review. Eur J Health Econ. 2019;20(3):407\u201317.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1341_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","volume":"17","author":"M Sekhon","year":"2017","unstructured":"Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):88.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1341_CR44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13063-016-1391-4","volume":"17","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Rooshenas L, Jepson M, Elliott D, Wade J, Avery K, et al. Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI). Trials. 2016;17(1):283.","journal-title":"Trials"},{"issue":"2","key":"1341_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"6","key":"1341_CR46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"1341_CR47","doi-asserted-by":"publisher","first-page":"e14588","DOI":"10.1111\/dme.14588","volume":"38","author":"G Ayman","year":"2021","unstructured":"Ayman G, Strachan JA, McLennan N, Malouf R, Lowe-Zinola J, Magdi F, et al. The top 10 research priorities in diabetes and pregnancy according to women, support networks and healthcare professionals. Diabet Med. 2021;38.","journal-title":"Diabet Med."},{"key":"1341_CR48","unstructured":"ICJME. Defining the role of authors and contributors 2022. Available from: https:\/\/www.icmje.org\/recommendations\/browse\/roles-and-responsibilities\/defining-the-role-of-authors-and-contributors.html#:~:text=The%20ICMJE%20recommends%20that%20authorship,for%20important%20intellectual%20content%3B%20AND."}],"container-title":["Pilot and Feasibility Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-023-01341-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40814-023-01341-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-023-01341-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T16:56:51Z","timestamp":1702745811000},"score":1,"resource":{"primary":{"URL":"https:\/\/pilotfeasibilitystudies.biomedcentral.com\/articles\/10.1186\/s40814-023-01341-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1341"],"URL":"https:\/\/doi.org\/10.1186\/s40814-023-01341-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2322264\/v1","asserted-by":"object"}]},"ISSN":["2055-5784"],"issn-type":[{"value":"2055-5784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"28 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UK Health Research Authority (HRA) and ethical approval for the use of human participants has been granted by the South Central Berkshire B Research Ethics Committee (REC; Reference: 22\/SC\/0246). All participants will be required to give informed, written consent to participate in the study. Where amendments to the protocol or documents are required, relevant approvals will be sought from the HRA. The Chief Investigator will be responsible for decisions to amend the protocol and to determine whether it is substantial or non-substantial, in liaison with the Sponsor (NBT). Amendments to the protocol will be documented using sequential version numbers, with updated documents replaced in the site files.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}